32 completed. 32 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 32 | Completed 32 |
| Phase 2 | 7 | Completed 7 |
Follow Atrophy: new trials by email Literature Review of Atrophy trials Research Report on Atrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pediatric Oncology Nutrition Intervention Trial Oral Nutrition Supplement, Tube Feed, Cyproheptadine - Pediatric Cancer, Nutrition Related Cancer | Phase 2 / Phase 3 | Completed | Corey Hawes | 20 | 2024-01-31 | 2026-10-08 |
| Effect Of Ophiochepalus Striatus Extract On Serum IGF-1 And IL-6 Levels In Elderly Patients With Sarcopenia Ophiochepalus striatus extract, Placebo - Sarcopenia, Geriatric | Phase 2 / Phase 3 | Completed | Universitas Sriwijaya | 80 | 2023-05-01 | 2025-01-31 |
| Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam OAV101 - Spinal Muscular Atrophy | Phase 3 | Completed | Novartis Pharmaceuticals | 27 | 2023-01-12 | 2026-01-13 |
| Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam Apitegromab, Placebo - Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3 | Phase 3 | Completed | Scholar Rock, Inc. | 188 | 2022-04-14 | 2026-01-22 |
| Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA) OAV101, Sham control - Type 2 Spinal Muscular Atrophy | Phase 3 | Completed | Novartis Pharmaceuticals | 126 | 2022-02-01 | 2026-01-13 |
| Growth Hormone in Decompensated Liver Cirrhosis Growth Hormone - Liver Cirrhosis, Fibrosis | Phase 2 / Phase 3 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 96 | 2022-02-01 | 2025-12-16 |
| Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) OAV101 - Spinal Muscular Atrophy | Phase 3 | Completed | Novartis Pharmaceuticals | 24 | 2021-09-08 | 2024-10-09 |
| Starting a Testosterone and Exercise Program After Hip Injury Testosterone, Placebo gel, Supervised exercise training - Hip Fracture, Frailty | Phase 3 | Completed | Washington University School of Medicine | 129 | 2019-03-05 | 2025-02-04 |
| Effect of Whole Body Electromyostimulation and/or Protein Supplementation on Sarcopenic Obesity in 70+ Whole body Electromyostimulation (exercise), Protein - Sarcopenic Obesity | Phase 3 | Completed | University of Erlangen-Nürnberg Medical School | 100 | 2016-08-01 | 2017-05-02 |
| Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy estrace cream (Perrigo), estrace cream (Reference), Placebo cream - Atrophy | Phase 3 | Completed | Padagis LLC | 695 | 2016-05-01 | 2021-11-02 |
| Carnitine Supplementation and Skeletal Muscle Function carnitine, placebo - Sarcopenia | Phase 3 | Completed | Gdansk University of Physical Education and Sport | 28 | 2016-02-01 | 2019-05-23 |
| An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 Bimagrumab, Placebo - Sporadic Inclusion Body Myositis | Phase 3 | Completed | Novartis Pharmaceuticals | 211 | 2015-11-02 | 2018-03-13 |
| Effect of Ursolic Acid of Loquat Extract on Function of Muscle UA group - Sarcopenia | Phase 2 / Phase 3 | Completed | Pusan National University Hospital | 54 | 2014-11-01 | 2015-11-03 |
| Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients BYM338/bimagrumab, Placebo - Sporadic Inclusion Body Myositis | Phase 2 / Phase 3 | Completed | Novartis Pharmaceuticals | 251 | 2013-09-26 | 2017-08-11 |
| Resistance Exercise, Muscle Mass, Strength and Body Composition HIT-exercise, low repetition range, HIT-exercise, high repetition range, HIT-exercise with protein - Sarcopenia, Obesity | Phase 3 | Completed | University of Erlangen-Nürnberg Medical School | 120 | 2013-01-01 | 2014-03-21 |
| The Effect of Alfacalcidol on Muscle Strength in Elderly Indonesian Women : A Randomized Controlled Trial alfacalcidol - Muscle Weakness | Phase 3 | Completed | Universitas Indonesia | 122 | 2012-04-01 | 2014-12-30 |
| Testosterone Administration and ACL Reconstruction in Men Testosterone, Placebo - Muscle Atrophy, ACL Reconstruction | Phase 3 | Completed | University of Southern California | 14 | 2012-04-01 | 2022-03-02 |
| Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum GTx-024, placebo - Muscle Wasting, Non-Small Cell Lung Cancer | Phase 3 | Completed | GTx | 330 | 2011-07-01 | 2020-11-09 |
| Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) GTx-024, placebo - Muscle Wasting, Non Small Cell Lung Cancer | Phase 3 | Completed | GTx | 321 | 2011-07-01 | 2016-03-03 |
| Evaluation of an Oral Nutritional Supplement Containing AN777 medical food with AN777, oral nutritional formula - Malnutrition, Sarcopenia | Phase 3 | Completed | Abbott Nutrition | 331 | 2011-02-01 | 2013-03-07 |
Showing 20 of 32. Sign in to see all of them.
Sarcopenia (13) · Muscular Atrophy (12) · Vaginal Diseases (5) · Muscular Atrophy, Spinal (4) · Muscular Diseases (3) · Amyotrophic Lateral Sclerosis (2) · Bulbo-Spinal Atrophy, X-Linked (2) · Carcinoma, Non-Small-Cell Lung (2) · Motor Activity (2) · Myositis, Inclusion Body (2) · Obesity (2) · Osteoporosis (2) · Spinal Muscular Atrophies of Childhood (2) · Acidosis (1)
Pathological Conditions, Anatomical (32) · Pathological Conditions, Signs and Symptoms (32) · Nervous System Diseases (25) · Neurologic Manifestations (25) · Signs and Symptoms (25) · Neuromuscular Manifestations (24) · Muscular Atrophy (13) · Musculoskeletal Diseases (10) · Nutritional and Metabolic Diseases (9) · Neuromuscular Diseases (7) · Central Nervous System Diseases (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Genital Diseases (6)
Ospemifene (5) · Proteins (2) · Testosterone (2) · Zolgensma (2) · bimagrumab (2) · mecobalamin (2) · ostarine (2) · Carnitine (1) · Creatine (1) · Cyproheptadine (1) · Enteral Nutrition (1) · Exercise (1) · Growth Hormone (1) · Olanzapine (1) · Pliability (1)
Novartis Pharmaceuticals (5) · Shionogi (5) · University of Erlangen-Nürnberg Medical School (3) · Eisai Co., Ltd. (2) · GTx (2) · University of Saskatchewan (2) · Abbott Nutrition (1) · Corey Hawes (1) · Gdansk University of Physical Education and Sport (1) · Kantonsspital Baselland Bruderholz (1) · Padagis LLC (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Pusan National University Hospital (1) · Scholar Rock, Inc. (1) · Universitas Indonesia (1)
United States (14) · Belgium (6) · Italy (6) · Canada (5) · France (5) · Japan (5) · United Kingdom (5) · Australia (4) · Germany (4) · Netherlands (4) · Switzerland (4) · Denmark (3) · Poland (3) · Spain (3) · India (2)
Wolfgang Kemmler, PhD (3) · Kazunori Saeki (2) · Klaus Engelke, PhD (2) · Andreas Wittke, MA (1) · Anja Weissenfels, MA (1) · Corey J Hawes, DCN, RD, CSO, CNSC, LD (1) · Cornel Sieber, MD (1) · Darren Candow, Ph.D. (1) · Ellen F Binder, MD (1) · Ellen Freiberger, PhD (1) · Iin Anugrahini (1) · Jay Magaziner, PhD (1) · Kenneth B Schechtman, PhD (1)
PMID 27138015, PMID 23361170, PMID 25481088, PMID 25923603, PMID 25973477, PMID 25982504, PMID 27780567, PMID 27999607, PMID 28220197, PMID 28840147, PMID 29216285, PMID 29523089, PMID 29675640, PMID 30636701, PMID 31397289, PMID 32761398, PMID 33345059, PMID 33597289, PMID 34107512, PMID 36070134, PMID 37619252, PMID 38525752, PMID 39804575, PMID 40372752, PMID 40818473, PMID 41360993, PMID 41360995, PMID 41475066, PMID 41624165
2015 (1), UL1TR001998 (1)